Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.76 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.76 |
| ▸ | CTSD | P07339 | 5/20 | 0.68 |
| ▸ | CTSE | P14091 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347302 | 0.88 | BACE1 (0.81) | BACE1BACE2CTSDCTSE | |
| SCHEMBL3353951 | 0.87 | BACE1 (0.77) | BACE1BACE2CTSDCTSE | |
| SCHEMBL3349454 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL3348990 | 0.86 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL3350500 | 0.86 | BACE1 (0.77) | BACE1BACE2CTSDCTSE | |
| SCHEMBL3350491 | 0.86 | BACE1 (0.77) | BACE1BACE2CTSDCTSE | |
| SCHEMBL5099109 | 0.86 | BACE1 (0.77) | BACE1BACE2CTSDCTSE | |
| SCHEMBL3348399 | 0.85 | BACE1 (0.81) | BACE1BACE2CTSDCTSE | |
| SCHEMBL3351088 | 0.85 | BACE1 (0.84) | BACE1BACE2CTSDCTSE | |
| SCHEMBL5180653 | 0.85 | BACE1 (0.76) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-7034182-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-25 | — | — | US | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | BACE1 6/4885BACE2 11/4885CTSD 1523/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | BACE1 12/4885BACE2 49/4885CTSD 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.